REGN news

• Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

  GlobeNewsWire · Oct 16, 2026
• 2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.

  Defense World · Oct 16, 2026
• Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More

  247 Wallst · Oct 15, 2026
• Longleaf Partners Global Fund Q3 2026 Portfolio Review

  Seeking Alpha · Oct 14, 2026
• These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  Zacks Investment Research · Oct 14, 2026
• Longleaf Partners Fund Q3 2026 Portfolio Review

  Seeking Alpha · Oct 14, 2026
• These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

  Zacks Investment Research · Oct 13, 2026
• Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by NorthCrest Asset Manangement LLC

  Defense World · Oct 13, 2026
• Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth

  Benzinga · Oct 12, 2026
• Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

  Zacks Investment Research · Oct 12, 2026
• Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

  GlobeNewsWire · Oct 12, 2026
• Why Regeneron (REGN) is a Top Value Stock for the Long-Term

  Zacks Investment Research · Oct 9, 2026
• Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies

  Defense World · Oct 6, 2026
• Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Central Pacific Bank Trust Division

  Defense World · Oct 6, 2026
• Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

  GlobeNewsWire · Oct 6, 2026
• Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data

  Benzinga · Oct 2, 2026
• Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

  Zacks Investment Research · Oct 2, 2026
• Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)

  Defense World · Oct 2, 2026
• Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript

  Seeking Alpha · Oct 1, 2026
• Regeneron And Sanofi Announce A Win-Win Collaboration Expansion

  Seeking Alpha · Oct 1, 2026
• Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

  GlobeNewsWire · Oct 1, 2026
• Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

  GlobeNewsWire · Oct 1, 2026
• Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion

  MarketBeat · Oct 1, 2026
• Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

  Zacks Investment Research · Oct 1, 2026
• Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion

  MarketBeat · Oct 1, 2026
• Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

  WSJ · Oct 1, 2026
• Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

  Reuters · Oct 1, 2026
• Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

  GlobeNewsWire · Oct 1, 2026
• Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

  GlobeNewsWire · Oct 1, 2026
• Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial

  Reuters · Sep 30, 2026

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.